BP11122 PLGA 65:35, Lauryl Ester Terminated, IV: 0.25–0.35 dl/g, Mw: 24–38 kDa

PLGA 65:35, Lauryl Ester Terminated, IV: 0.25–0.35 dl/g, Mw: 24–38 kDa Description

This polymer is a copolymer of lactic and glycolic acids with a 65:35 ratio and lauryl ester termination, which modifies its hydrophobic characteristics. The controlled intrinsic viscosity (0.25–0.35 dl/g) alongside a molecular weight of 24–38 kDa underpins its predictable degradation behaviour. The product is formulated to achieve specific performance criteria in applications that require calibrated degradation rates, such as drug delivery systems and tissue engineering scaffolds.

PLGA 65:35, Lauryl Ester Terminated, IV: 0.25–0.35 dl/g, Mw: 24–38 kDa Applications

1.         Healthcare and Biomedical Devices
   - Used as a matrix component in drug delivery systems to achieve controlled release by leveraging its predictable degradation rate.
   - Applied as a scaffold in tissue engineering to facilitate cell growth while gradually degrading, reducing the need for secondary surgical removal.

2.         Pharmaceutical Manufacturing
   - Utilised as a vehicle for encapsulating active pharmaceutical ingredients, ensuring consistent dissolution profiles by capitalising on controlled molecular weight.
   - Employed in bioresorbable implant formulations to provide temporary structural support with predictable breakdown kinetics.

PLGA 65:35, Lauryl Ester Terminated, IV: 0.25–0.35 dl/g, Mw: 24–38 kDa Packing

The polymer is packaged in moisture-impermeable, sealed containers to protect against humidity and contamination. Each package is enclosed within secondary protective layers to prevent physical damage during transit. Storage under temperature-controlled, dry conditions is recommended to maintain material properties. Custom packaging solutions, including bulk and unitised formats, are available to meet specific logistical requirements.

Additional Information

Advanced biocompatible polymeric materials such as PLGA are pivotal in the development of next-stage biomedical devices. These materials have well-defined degradation characteristics that align with the therapeutic objectives of various medical implants and drug delivery systems. The interplay between molecular weight, intrinsic viscosity, and end-group modifications significantly influences the material's behaviour, thereby enabling precise control over its in vivo performance.

In research and development, the systematic study of polymer degradation kinetics supports the design of applications that require predictable resorption rates. Understanding these interactions aids in the rational design of formulations for applications ranging from regenerative medicine to controlled pharmaceutical release.

Regulatory Note: This material is intended for industrial and research applications. It is the customer's responsibility to ensure compliance with all relevant safety and regulatory standards in their intended use.